Metallo‐β‐lactamases (MBLs) cause resistance of Gram‐negative bacteria to β‐lactam antibiotics and are of serious concern, because they can inactivate the last‐resort carbapenems and because MBL inhibitors of clinical value are still lacking. We previously identified the original binding mode of 4‐amino‐2,4‐dihydro‐5‐(2‐methylphenyl)‐3H‐1,2,4‐triazole‐3‐thione (compound IIIA) within the dizinc active site of the L1 MBL. Herein we present the crystallographic structure of a complex of L1 with the corresponding non‐amino compound IIIB (1,2‐dihydro‐5‐(2‐methylphenyl)‐3H‐1,2,4‐triazole‐3‐thione). Unexpectedly, the binding mode of IIIB was similar but reverse to that of IIIA. The 3 D structures suggested that the triazole–thione scaffold was suitable to bind to the catalytic site of dizinc metalloenzymes. On the basis of these results, we synthesized 54 analogues of IIIA or IIIB. Nineteen showed IC50 values in the micromolar range toward at least one of five representative MBLs (i.e., L1, VIM‐4, VIM‐2, NDM‐1, and IMP‐1). Five of these exhibited a significant inhibition of at least four enzymes, including NDM‐1, VIM‐2, and IMP‐1. Active compounds mainly featured either halogen or bulky bicyclic aryl substituents. Finally, some compounds were also tested on several microbial dinuclear zinc‐dependent hydrolases belonging to the MBL‐fold superfamily (i.e., endonucleases and glyoxalase II) to explore their activity toward structurally similar but functionally distinct enzymes. Whereas the bacterial tRNases were not inhibited, the best IC50 values toward plasmodial glyoxalase II were in the 10 μm range.
From carboxylic acid trifluoromethyl aziridines, halogeno β-lactams were obtained stereoselectively by ring expansion. Different conditions such as radical, organometallic reactions allowed easy and selective access to CF3-β-lactams substituted at the C-3 position.
To fight the increasingly worrying bacterial resistance to antibiotics, the discovery and development of new therapeutics is urgently needed. Here, we report on a new series of 1,2,4-triazole-3-thione compounds as inhibitors of metallo-β-lactamases (MBLs), which represent major resistance determinants to β-lactams, and especially carbapenems, in Gram-negative bacteria. These molecules are stable analogs of 4-amino-1,2,4-triazole-derived Schiff bases, where the hydrazone-like bond has been reduced (hydrazine series) or the 4-amino group has been acylated (hydrazide series); the synthesis and physicochemical properties thereof are described. The inhibitory potency was determined on the most clinically relevant acquired MBLs (IMP-, VIM-, and NDM-types subclass B1 MBLs). When compared with the previously reported hydrazone series, hydrazine but not hydrazide analogs showed similarly potent inhibitory activity on VIM-type enzymes, especially VIM-2 and VIM-4, with Ki values in the micromolar to submicromolar range. One of these showed broad-spectrum inhibition as it also significantly inhibited VIM-1 and NDM-1. Restoration of β-lactam activity in microbiological assays was observed for one selected compound. Finally, the binding to the VIM-2 active site was evaluated by isothermal titration calorimetry and a modeling study explored the effect of the linker structure on the mode of binding with this MBL.
By exploiting the dual reactivity of a Weinreb amide moiety, i.e. nucleophilic addition or N–O reductive cleavage, a series of diversified symmetrical and dissymmetrical pyrrolidine analogues of lobelanine were synthesized from simple and readily available building blocks. Diversity is introduced at a late stage by using a wide variety of readily available organolithium and organomagnesium reagents, and chemoselective orientation can be achieved due to the steric encumbrance of both the reaction partners, the liganding ability of the starting meso pyrrolidine, and the nature of the organometallic species. This work constitutes the first example that takes advantage of the side reaction of Weinreb amide decomposition for the desymmetrization of a meso platform bearing two remote and highly flexible N-methoxy-N-methylamide arms through a probable beneficial metal-templated arrangement.
La propagation de bactéries à Gram négatif multirésistantes aux antibiotiques représente un problème de santé publique majeur urgent à résoudre car le risque d’un retour à l’ère pré-antibiotique est réel. Parmi les modes de résistance existant, la production de métallo-B-lactamases (MBLs) responsables de l’inactivation des B-lactamines, la famille d’antibiotiques la plus utilisée, représente un challenge thérapeutique.Les travaux décrits dans ce manuscrit concernent la synthèse, la caractérisation et l’évaluation biologique de composés construits autour d’un cœur 2,4-dihydro-3H-1,2,4-triazole-3-thione substitués en deux positions. En se basant sur des études de criblage in silico et des études cristallographiques ayant permis d’identifier ce noyau comme un bon candidat dans le développement d’inhibiteurs de MBLs, la synthèse de différentes séries d’analogues a été entreprise afin d’identifier de nouveaux inhibiteurs pouvant potentiellement atteindre les tests cliniques.Dans un premier temps, une série de composés 4-amino-1,2,4-triazole-3-thione substitués en position 5 a été préparée en suivant des voies de synthèse classiques. Différentes séries ont ensuite été développées en introduisant une diversité structurale et fonctionnelle en position 4. Ces composés ont ensuite été testés sur des enzymes représentatives des 3 sous-classes de MBLs et les plus intéressants ont été évalués sur bactéries résistantes recombinantes.Afin de réaliser une évaluation rapide des produits synthétisés au sein du laboratoire, une méthode de criblage à moyen débit en plaque 96 puits sur cinq MBLs représentatives a été mise au point et validée grâce à l’appui de nos collaborateurs spécialistes des MBLs.